Euronext Paris · Healthcare
Invest in Valerio Therapeutics stock from India
Indian and foreign residents can buy Valerio Therapeutics (ALVIO) shares directly through Paasa.
By Paasa · Updated
Valerio Therapeutics at a glance
- Price
- €0.53-€0.02 (3.63%)
- Market cap
- €265.21M
- Day range
- €0.52 – €0.55
- P/E
- -16.75
- Dividend yield
- None
- Volume
- 578.32K
- 1 month
- -31.31%
- 6 months
- +369.91%
- YTD
- +284.78%
- 1 year
- +812.37%
- 5 years
- —
Valerio Therapeutics statements, FY2021–FY2025
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | €2.6M | €1.8M | €1.8M | €1.4M | €4.1M |
| Gross profit | €1.7M | €1.3M | €1.3M | €929.0K | €3.7M |
| Operating income | −€550.0K | −€16.5M | −€20.3M | −€17.1M | −€7.3M |
| Net income | −€4.9M | −€23.9M | −€20.3M | −€19.6M | −€5.9M |
| Earnings per share | −€0.03 | −€0.16 | −€0.15 | −€0.18 | −€0.07 |
| EBITDA | €542.0K | −€12.1M | −€18.4M | −€17.0M | −€5.9M |
| Total assets | €15.2M | €17.9M | €35.3M | €43.1M | €53.1M |
| Total debt | €7.6M | €13.4M | €9.0M | €10.1M | €9.9M |
| Cash and short-term investments | €1.1M | €1.2M | €6.8M | €14.6M | €17.9M |
| Shareholders' equity | €2.1M | −€8.9M | €14.8M | €22.3M | €32.9M |
| Operating cash flow | €1.8M | −€12.5M | −€18.6M | −€9.4M | −€8.6M |
| Free cash flow | €521.0K | −€12.8M | −€18.8M | −€9.9M | −€8.7M |
| Capital expenditure | −€1.3M | −€319.0K | −€183.0K | −€488.0K | −€139.0K |
Fiscal years as reported, the latest ending 31 Dec 2025. Figures in EUR; a dash means the provider reported nothing for that line.
Peer comparison
| Company | Ticker | Price | Market cap |
|---|---|---|---|
| Theraclion | ALTHE.PA | €0.69 | €50.74M |
| Novacyt | ALNOV.PA | €0.50 | €35.89M |
| Nicox | ALCOX.PA | €0.33 | €32.47M |
| genOway | ALGEN.PA | €2.34 | €28.88M |
| Valbiotis | ALVAL.PA | €0.69 | €24.49M |
| Diagnostic Medical Systems | ALDMS.PA | €0.91 | €23.50M |
| Implanet | ALIMP.PA | €0.16 | €23.01M |
| GenSight Biologics | SIGHT.PA | €0.10 | €16.20M |
Peers as grouped by the data provider. This is not an investment recommendation.
How to invest in Valerio Therapeutics from India
Step 1
Open your Paasa account
KYC takes a few minutes: PAN, Aadhaar and address proof. Your brokerage account is opened in your own name with Interactive Brokers.
Step 2
Add funds from your Indian bank account
Remit up to $250,000 a year under the RBI's Liberalised Remittance Scheme. Your bank converts the rupees to US dollars at its rate on the day you remit, and Interactive Brokers converts the dollars to EUR when you buy.
Step 3
Search ALVIO and buy
Find Valerio Therapeutics by name or by its ticker, ALVIO, and place your order.
Why invest in Valerio Therapeutics from India
What Valerio Therapeutics does
Headquartered in Paris, France, and founded in 1997, Valerio Therapeutics S.A. (known as Onxeo SA until June 2023) is a clinical-stage biotechnology company dedicated to the global research and development of oncology treatments. Their focus is on targeting the DNA repair processes crucial for tumor survival. Valerio Therapeutics operates in the Biotechnology industry within the Healthcare sector.
Paasa handles the paperwork
Investing abroad brings paperwork with it: remittance filings, capital gains reporting, foreign asset disclosure. Paasa prepares all of it for you. Your India-ready tax reports arrive at year end, ready to file.
Frequently asked questions
Can I buy Valerio Therapeutics stock from India?
Yes. Indian residents and NRIs can buy Valerio Therapeutics (ALVIO) shares directly through Paasa. Valerio Therapeutics is listed on Euronext Paris, in the Biotechnology industry. Your money leaves India under the RBI's Liberalised Remittance Scheme and the shares are held in your own name at Interactive Brokers.
What tax do I pay in India when I sell Valerio Therapeutics shares?
In India, gains on shares held for more than 24 months are long-term and taxed at 12.5%, and gains on shares held for 24 months or less are short-term and taxed at your income-tax slab rate. Both are worked out in rupees at the EUR/INR rate on the day you bought and the day you sold, so the currency move is part of the gain. Paasa's capital-gains statement gives you the figures for your return.